The National Diabetes Education Program: Changing the Way Diabetes Is Treated
Authors: Charles M. Clark
Journal: Annals of Internal Medicine (1999)

Editorials16 February 1999The National Diabetes Education Program: Changing the Way Diabetes Is TreatedCharles M. Clark Jr., MDCharles M. Clark Jr., MDIndiana University School of Medicine; Indianapolis, IN 46202 (Clark)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-130-4-199902160-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The past few years have been exciting for those of us who treat persons with diabetes. After decades of debate, the evidence that diabetes treatment can prevent or markedly reduce many of the long-term complications of the disease has now become overwhelming. Recent epidemiologic and prospective therapeutic trials examining this hypothesis have found that glycemic control will reduce the microvascular complications of diabetes in patients with either type of the disease (Table). The pivotal trial for patients with type 1 diabetes was the Diabetes Control and Complications Trial, a 10-year trial that was reported in 1993 and sponsored by the ...References1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329:977-86. Google Scholar2. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al . Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non–insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-17. CrossrefMedlineGoogle Scholar3. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995;18:258-68. CrossrefMedlineGoogle Scholar4. Intensive bloo d-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352:837-53. Google Scholar5. Effect of intensive bloo d-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352:854-65. Google Scholar6. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19 Suppl 789-830. Google Scholar7. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, et al . Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57-65. CrossrefMedlineGoogle Scholar8. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 1998; 21(Suppl 1): S23-S31. Google Scholar9. Center for Economic Studies in Medicine. Direct and Indirect Costs of Diabetes in the United States in 1992. Alexandria, VA: American Diabetes Association; 1993. Google Scholar10. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. In: Third National Health and Nutrition Examination Survey, 1988-1994. Hyattsville, MD: U.S. Dept. of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 1994. Google Scholar11. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317:703-13. Google Scholar12. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998; 317:713-20. Google Scholar13. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614-20. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Charles M. ClarkJr., MDAffiliations: Indiana University School of Medicine; Indianapolis, IN 46202 (Clark)Corresponding Author: Charles M. Clark Jr., MD, Indiana University School of Medicine, Regenstrief Health Center, Fifth Floor, 1001 West 10th Street, Indianapolis, IN 46202. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byGroup based diabetes self-management education compared to routine treatment, waiting list control or no intervention for people with type 2 diabetes mellitusGroup based training for self-management strategies in people with type 2 diabetes mellitusGroup Diabetes Patient Education: A MODEL FOR USE IN A CONTINUING CARE RETIREMENT COMMUNITYLipoatrophic Diabetes MellitusIncorporating the Results of Diabetes Research Into Clinical PracticeQuality of care and diabetes mellitusReport of the Health Care Delivery Work GroupDiabetes mellitus type 2: geen tweederangsziekteMetformin as secondary therapy in a defined population with type 2 diabetes 16 February 1999Volume 130, Issue 4_Part_1Page: 324-326KeywordsHemoglobinHyperglycemiaHyperlipidemiaHypertensionInsulinMedical risk factorsOverweightPrevention, policy, and public healthType 2 diabetesVeteran care ePublished: 15 August 2000 Issue Published: 16 February 1999 Copyright & PermissionsCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...